#United States #Class Action #Los Angeles #Securities Fraud #Capricor Therapeutics

Investors Unite for Class Action Against Capricor Therapeutics

In a significant development for investors, Schall, Brown & Schwartz LLP (SBS), a leading national shareholder rights litigation firm, has called attention to a major class action lawsuit filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR). The lawsuit pertains to alleged violations of the Securities Exchange Act of 1934 and Rule 10b-5 of the U.S. Securities and Exchange Commission.

Class Period and Deadlines

The class period for this lawsuit spans from December 17, 2025, to July 26, 2026, and interested shareholders have until September 28, 2026, to voice their claims and potentially serve as lead plaintiffs in this case. Those who acquired shares within this time frame are encouraged to contact SBS to discuss their rights and possibilities for recovery.

Details of the Case

According to the complaint filed by SBS, Capricor has made misleading statements to the market, specifically regarding the clinical data for a treatment known as Deramiocel. It has come to light that the company altered the statistical analysis plan related to the clinical data without receiving prior FDA approval, raising significant concerns regarding the chances of securing FDA approval for Deramiocel's Biologics License Application (BLA). This lack of sufficient evidence of effectiveness further complicates the situation.

The consequence of these actions is alarming: during the class period, investors sustained substantial losses due to Capricor’s miscommunications and the subsequent revelation of the truth surrounding the FDA approval process.

Call to Action

If you are among those who have incurred losses as a result of investing in Capricor Therapeutics, now is the time to act. In addition to filing claims, investors can also join forces to recover their lost investments. SBS is reaching out to potential plaintiffs to consider their options in this ongoing legal situation.

Why Choose SBS?

SBS is highly regarded for its commitment to representing investors globally and specializes in securities class action lawsuits. With expertise stemming from experienced partners, including Brian Schall, Andrew Brown, and David Schwartz, the firm emphasizes tenacious advocacy for every client. They operate under a client-focused philosophy, aiming to safeguard the rights and interests of investors who have endured losses.

Final Thoughts

With the complexities of investing and the accompanying risks, navigating securities fraud allegations requires expert guidance. For investors in Capricor Therapeutics, the opportunity to reclaim losses via this class action lawsuit represents a pivotal moment. Interested shareholders should not hesitate to get in touch with SBS for a free consultation regarding their rights and participation in this critical lawsuit.

For more information, investors can contact Brian Schall or David Schwartz directly at SBS, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. Call 310-301-3335, or visit the firm’s website at www.schallfirm.com.

Disclaimer: This press release may fall under Attorney Advertising in certain jurisdictions. Interested parties should remain aware that the class has not yet been certified; thus, until certification, individuals are not represented by an attorney if no action is taken.